H.C. Wainwright analyst Yi Chen reiterated a Buy rating on BioLife Solutions today and set a price target of $32.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Yi Chen has given his Buy rating due to a combination of factors including BioLife Solutions’ recent strategic developments and financial performance. The opening of the Aby J. Mathew Center for Biopreservation Excellence is a significant milestone, showcasing the company’s comprehensive product portfolio and advancing innovation in biopreservation and cell processing. This new facility is expected to enhance best practices and increase the utilization of BioLife’s offerings within the cell and gene therapy industry.
Additionally, the company’s financial results for the third quarter of 2025 exceeded expectations, with a notable 31% year-over-year revenue growth and a positive net income, surpassing prior loss estimates. The divestment of the evo cold chain logistics business has streamlined operations, contributing to a strong cash position and enabling a focused growth strategy. BioLife’s substantial market share in biopreservation media and involvement in numerous clinical trials further support the positive outlook, with potential upcoming product approvals and geographic expansions anticipated to drive future growth.
According to TipRanks, Chen is an analyst with an average return of -8.0% and a 39.24% success rate. Chen covers the Healthcare sector, focusing on stocks such as RegenXBio, Formycon AG, and VolitionRX.
In another report released on November 11, Maxim Group also reiterated a Buy rating on the stock with a $34.00 price target.